4 Results for "

cytoskeletal organization

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "cytoskeletal organization" in MCE Product Catalog:

Cat. No.: HY-175843
Target:  

ROCK STAT

Research Areas:  

Cancer

ROCK2-IN-10 is a potent and selective ROCK2 inhibitor (IC50 = 0.020 μM) with 41-fold selectivity over isoform ROCK1. ROCK2-IN-10 inhibits metastasis by disrupting the cytoskeleton, independent of proliferative suppression. ROCK2-IN-10 shows superior inhibitory potency against cancer cell metastasis, which closely related to the suppression of STAT3 phosphorylation. ROCK2-IN-10 can be used for breast cancer metastasis research .
loading...
    loading...
Cat. No.: HY-187757
CAS No.: 77749-81-6
Research Areas:  

Cancer

RX-RA 85 is an orally active phosphodiesterase modulator that exerts antiplatelet and antitumor effects by elevating intracellular cAMP levels, inhibiting platelet and tumor cell PDE activity, and modulating cytoskeletal organization. RX-RA 85 can be used in studies of rat breast cancer and metastatic tumors .
loading...
    loading...
Cat. No.: HY-101145
CAS No.: 1001478-90-5
Research Areas:  

Cancer

CK37 is a competitive choline kinase-α inhibitor. CK37 inhibits purified recombinant human choline kinase-α activity. CK37 suppresses MAPK and PI3K/AKT signaling, disrupts actin cytoskeletal organization. CK37 diminishs activating phosphorylations of ERK. CK37 exhibits anticancer activity against cervical cancer, melanoma, Lewis lung carcinoma, lung adenocarcinoma, breast cancer, and leukemia .
loading...
    loading...
Cat. No.: HY-187204
Target:  

ROCK

Research Areas:  

Neurological Disease

RX-044 is a ROCK1/ROCK2 inhibitor with ROCK1 IC50 10.01 nM and ROCK2 IC50 9.68 nM, and demonstrates kinase selectivity. RX-044 induces reversible cell retraction, modulates cytoskeletal organization via F-actin depolymerization, inhibits cell contractility, and attenuates TGF-β2-induced cell migration. RX-044 preserves retinal ganglion cell survival, restores electroretinography responses, and ameliorates histopathological changes. RX-044 lowers intraocular pressure in a mouse ocular hypertension model. RX-044 shows no cytotoxicity in target cells. RX-044 exhibits initial ocular irritation that subsides with extended dosing. RX-044 can be used for the research of glaucoma .
loading...
    loading...